Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
Highlight
– Multicentre TriNetX analysis (Kitano et al., 2025) examined association between timing of last nirsevimab dose and RSV test-positivity among children <24 months tested for RSV (Jul 2023–Jun 2025).
– Receiving nirsevimab within 6 months of testing halved the odds of a positive RSV test (OR 0.49; 95% CI 0.42–0.57); protection persisted, though attenuated, when dose was 6–11 months prior (OR 0.67; 95% CI 0.48–0.94).
– No significant protective association was seen when last dose was >12 months before testing (OR 1.21; 95% CI 0.89–1.65). Findings are hypothesis generating and limited by confounding and database constraints.
Background and disease burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.